Chronic Hepatitis B (CHB) Market to Reach $10.9 Billion by 2034, Growing at a 6.8% CAGR

Introduction
Chronic Hepatitis B (CHB) remains one of the most serious and persistent viral infections affecting the human liver, posing major global health and economic challenges. Despite the availability of effective vaccines and antiviral treatments, more than 250 million people worldwide continue to live with chronic HBV infection, placing them at risk of liver cirrhosis and hepatocellular carcinoma (HCC).

According to Exactitude Consultancy, the Global Chronic Hepatitis B (CHB) Epidemiology and Clinical Market is projected to reach USD 10.9 billion by 2034, growing at a CAGR of 6.8% from 2024 to 2034. This expansion is driven by the increasing global prevalence of CHB, improved diagnostic and surveillance programs, the emergence of novel antiviral and immunomodulatory therapies, and intensified public health efforts to achieve WHO's target of eliminating hepatitis B as a public health threat by 2030.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/73640

Market Overview
Chronic Hepatitis B is caused by long-term infection with the Hepatitis B Virus (HBV), which attacks the liver and can lead to chronic inflammation, fibrosis, and liver cancer. Despite extensive vaccination programs, HBV continues to be a major global health concern, particularly in Asia-Pacific and sub-Saharan Africa, where vertical transmission (from mother to child) and lack of vaccination coverage remain widespread.
The CHB clinical and epidemiological market encompasses diagnostics, therapeutics, vaccines, surveillance programs, and epidemiological research aimed at identifying trends, patient demographics, and treatment outcomes.

Key Market Highlights (2024-2034)
• Market Size (2024): USD 5.7 Billion
• Forecast Size (2034): USD 10.9 Billion
• CAGR (2024-2034): 6.8%
• Global CHB Patient Pool (2024): ~257 Million
• Primary Drivers: Rising prevalence, strong antiviral drug pipeline, and government-led vaccination initiatives
• Challenges: Treatment adherence, limited cure options, and regional disparities in healthcare access
• Key Players: Gilead Sciences, Johnson & Johnson, GlaxoSmithKline (GSK), Bristol Myers Squibb, Roche, and AbbVie

The market's growth reflects both an increasing global disease burden and the evolving therapeutic landscape focusing on functional cures through immune modulation and gene-based interventions.

Market Segmentation Analysis
By Treatment Type
• Antiviral Drugs
o Nucleos(t)ide Analogues
 Tenofovir (TDF, TAF)
 Entecavir
 Lamivudine
 Adefovir
o Interferon-Based Therapy
 Pegylated Interferon Alfa-2a & Alfa-2b
• Combination Therapies
o Antiviral + Immune Modulators
o Interferon + Nucleos(t)ide Analogue
• Pipeline & Emerging Therapies
o Capsid Assembly Modulators
o siRNA and RNA Interference Therapies
o Immune Checkpoint Modulators
o Therapeutic Vaccines

By Diagnostic Type
• Serological Tests (HBsAg, HBeAg, Anti-HBc)
• HBV DNA Quantification (PCR-based)
• Liver Biopsy & Imaging (Fibroscan, Ultrasound)
• Biomarker-Based Monitoring

By End User
• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Research Institutes & Epidemiology Centers
• Public Health Programs

By Region
• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• Latin America

Summary:
The antiviral drugs segment dominates the market, accounting for over 70% of total revenue in 2024, owing to the widespread use of tenofovir and entecavir as first-line therapies. However, the pipeline therapies segment is expected to register the highest CAGR of 9.1%, driven by the rise of combination regimens and novel mechanisms targeting viral replication and immune restoration. Diagnostic advancements, particularly quantitative HBV DNA testing and fibrosis imaging, are improving disease monitoring and treatment stratification globally.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/73640/chronic-hepatitis-b-chb-epidemiology-analysis-and-forecast-to-2034-market

Regional Analysis
North America
North America remains a major market due to strong healthcare infrastructure, advanced diagnostic capabilities, and early access to innovative antiviral therapies. The United States accounts for a significant portion of the regional market, supported by widespread screening programs and government-funded vaccination campaigns such as the CDC's Viral Hepatitis National Strategic Plan (2021-2030).
While overall incidence rates are relatively low due to vaccination success, the region faces challenges from undiagnosed chronic carriers and immigrant populations from endemic regions.

Europe
Europe holds a steady market share, with countries such as Germany, France, Italy, and the U.K. emphasizing HBV control through routine vaccination, screening during pregnancy, and harm-reduction programs for at-risk populations.
The European Association for the Study of the Liver (EASL) provides robust guidelines that standardize treatment protocols, promoting high antiviral adoption rates. Ongoing collaborations between public health agencies and pharmaceutical firms are further strengthening disease surveillance and real-world data generation.

Asia-Pacific
Asia-Pacific is the largest and fastest-growing region, accounting for over 55% of global CHB cases and a projected CAGR of 7.8% through 2034. Countries like China, India, South Korea, and Japan have massive patient populations, strong epidemiological programs, and increasing access to antiviral therapy.
China alone accounts for approximately 30% of global HBV infections, driving substantial government intervention through screening, vaccination, and perinatal prevention programs. The region's growth is further accelerated by increasing clinical trials and investment in local biopharmaceutical innovation.

Middle East & Africa
The Middle East & Africa region bears one of the world's highest HBV prevalence rates, exceeding 8% in several sub-Saharan nations. However, limited access to diagnostics and antiviral drugs continues to challenge market growth. WHO-backed initiatives and Gavi-supported vaccination campaigns are expected to enhance coverage and awareness, improving long-term outcomes.

Latin America
Latin America's market is expanding steadily, supported by vaccination programs and increased investment in healthcare infrastructure. Brazil and Mexico lead regional efforts in disease surveillance, treatment access, and epidemiological modeling.
Nevertheless, underreporting and limited diagnostic capacity remain barriers to consistent management and data collection.

Overall Regional Trend:
Asia-Pacific leads the global CHB epidemiology and therapeutics market, both in disease burden and investment. However, North America and Europe remain critical for R&D and regulatory advancements, while Africa and Latin America represent untapped potential for vaccination and antiviral expansion.

Market Dynamics
Key Growth Drivers
1. Rising Global Disease Burden
Despite extensive vaccination, HBV infection remains endemic in many regions. Over 1.5 million new infections occur annually, driven by perinatal and horizontal transmission.
2. Advances in Antiviral and Immunotherapy
Long-acting antivirals with improved safety profiles (e.g., tenofovir alafenamide) and emerging siRNA-based therapies are changing the treatment paradigm toward functional cure.
3. Government and WHO-Led Elimination Initiatives
The WHO Global Hepatitis Strategy 2030 aims to reduce new infections by 90% and mortality by 65%. This has accelerated funding, surveillance, and public health integration.
4. Improved Diagnostics and Disease Modeling
The adoption of molecular testing, non-invasive fibrosis assessment, and real-world epidemiological analytics has enabled precise disease monitoring.

Key Challenges
1. Lack of Curative Therapy
Current antivirals suppress viral replication but fail to fully eradicate covalently closed circular DNA (cccDNA), leading to relapse risk after treatment cessation.
2. Treatment Adherence and Monitoring
Lifelong therapy adherence remains low in low-income regions, driven by cost, limited healthcare follow-up, and stigma.
3. Uneven Global Access to Treatment
Disparities in drug affordability and healthcare infrastructure hinder universal access, especially in Africa and parts of Southeast Asia.

Latest Trends
• Shift Toward Functional Cure Strategies:
Companies are investing in novel therapeutics targeting HBV cccDNA and immune restoration to achieve long-term remission or cure.
• Integration of AI in Epidemiological Forecasting:
Artificial intelligence and predictive analytics are enhancing HBV prevalence mapping, patient identification, and treatment optimization.
• Expansion of Combination Therapies:
Ongoing trials are exploring antiviral plus immune modulator combinations to boost clearance rates.
• Rising Role of Public-Private Collaborations:
Partnerships among pharmaceutical companies, NGOs, and national health agencies are accelerating vaccine delivery and treatment rollout.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73640

Competitive Landscape
Major Players
• Gilead Sciences, Inc.
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson (Janssen Pharmaceuticals)
• F. Hoffmann-La Roche Ltd.
• Bristol Myers Squibb Company (BMS)
• AbbVie Inc.
• Arbutus Biopharma Corporation
• Assembly Biosciences, Inc.
• Vir Biotechnology, Inc.
• Aligos Therapeutics, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Replicor Inc.
• Eiger BioPharmaceuticals, Inc.
• Hepion Pharmaceuticals, Inc.
• Antios Therapeutics
• Myers Squibb Co.
• Enyo Pharma SA
• Janssen Biotech
• Spring Bank Pharmaceuticals
• Intercept Pharmaceuticals, Inc.

Competitive Summary
The CHB therapeutics market is moderately consolidated, with Gilead Sciences and GlaxoSmithKline leading through flagship antivirals such as Viread, Vemlidy, and Baraclude. Meanwhile, Bristol Myers Squibb and Roche remain active in interferon-based therapy and diagnostic solutions.
Emerging biotech firms-Arbutus, Assembly, Vir Biotechnology, and Arrowhead-are at the forefront of functional cure R&D, with novel RNAi and capsid assembly modulators in late-stage trials.
Strategic collaborations, co-development agreements, and licensing deals continue to shape the competitive landscape, as established players expand their hepatitis portfolios with next-generation therapeutics.

Conclusion
The global Chronic Hepatitis B (CHB) Epidemiology and Clinical Market is entering a pivotal phase of transformation. The combined momentum of scientific innovation, vaccination efforts, and enhanced global surveillance is steering the industry toward WHO's elimination goals.

Although curative therapies remain a future aspiration, rapid advancements in antiviral, immunomodulatory, and RNA-based treatments have laid the foundation for long-term disease control and improved patient quality of life.
By 2034, the market is expected to nearly double in value, driven by sustained government funding, growing awareness, and expansion of screening and treatment infrastructure across high-burden regions. As clinical and epidemiological insights deepen, the next decade will likely see a paradigm shift from chronic suppression to potential eradication.

This report is also available in the following languages : Japanese (慢性B型肝炎(CHB)疫学分析と2034年までの予測), Korean (만성 B형 간염(CHB) 역학 분석 및 2034년까지의 예측), Chinese (慢性乙型肝炎(CHB)流行病学分析及2034年预测), French (Analyse et prévisions épidémiologiques de l'hépatite B chronique (HBC) jusqu'en 2034), German (Epidemiologische Analyse und Prognose der chronischen Hepatitis B (CHB) bis 2034), and Italian (Infezioni da Clostridioides difficile (CDI)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73640

Our More Reports:

Wireless Panoramic Camera
https://exactitudeconsultancy.com/reports/75198/wireless-panoramic-camera-market

Pulse Safety Resistor
https://exactitudeconsultancy.com/reports/75200/pulse-safety-resistor-market

Bearing Installation Tool Kit
https://exactitudeconsultancy.com/reports/75202/bearing-installation-tool-kit-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.